

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1642BJF

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

| | | | |
|--------------|----|--------|--|
| NEWS | 1 | | Web Page URLs for STN Seminar Schedule - N. America |
| NEWS | 2 | | "Ask CAS" for self-help around the clock |
| NEWS | 3 | JUL 20 | Powerful new interactive analysis and visualization software, STN AnaVist, now available |
| NEWS | 4 | AUG 11 | STN AnaVist workshops to be held in North America |
| NEWS | 5 | AUG 30 | CA/CAPLUS - Increased access to 19th century research documents |
| NEWS | 6 | AUG 30 | CASREACT - Enhanced with displayable reaction conditions |
| NEWS | 7 | SEP 09 | ACD predicted properties enhanced in REGISTRY/ZREGISTRY |
| NEWS | 8 | OCT 03 | MATHDI removed from STN |
| NEWS | 9 | OCT 04 | CA/CAPLUS-Canadian Intellectual Property Office (CIPO) added to core patent offices |
| NEWS | 10 | OCT 06 | STN AnaVist workshops to be held in North America |
| NEWS | 11 | OCT 13 | New CAS Information Use Policies Effective October 17, 2005 |
| NEWS | 12 | OCT 17 | STN(R) AnaVist(TM), Version 1.01, allows the export/download of CAPLUS documents for use in third-party analysis and visualization tools |
| NEWS | 13 | OCT 27 | Free KWIC format extended in full-text databases |
| NEWS | 14 | OCT 27 | DIOGENES content streamlined |
| NEWS | 15 | OCT 27 | EPFULL enhanced with additional content |
| NEWS | 16 | NOV 14 | CA/CAPLUS - Expanded coverage of German academic research |
| NEWS EXPRESS | | | JUNE 13 CURRENT WINDOWS VERSION IS V8.0, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 13 JUNE 2005 |
| NEWS HOURS | | | STN Operating Hours Plus Help Desk Availability |
| NEWS INTER | | | General Internet Information |
| NEWS LOGIN | | | Welcome Banner and News Items |
| NEWS PHONE | | | Direct Dial and Telecommunication Network Access to STN |
| NEWS WWW | | | CAS World Wide Web Site (general information) |

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 15:51:38 ON 15 NOV 2005

=> file registry
COST IN U.S. DOLLARS

| SINCE FILE | TOTAL |
|------------|---------|
| ENTRY | SESSION |

6/10/05 2/10

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 15:51:48 ON 15 NOV 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 14 NOV 2005 HIGHEST RN 868046-42-8
DICTIONARY FILE UPDATES: 14 NOV 2005 HIGHEST RN 868046-42-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*

Structure search iteration limits have been increased. See HELP SLIMITS
for details.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> E "TER286"/CN 25

| | | |
|-----|-------|---|
| E1 | 1 | TER-SPEZIAL/CN |
| E2 | 1 | TER-SPEZIAL, MIXT. CONTG./CN |
| E3 | 0 --> | TER286/CN |
| E4 | 1 | TERA (HUMAN)/CN |
| E5 | 1 | TERA PROTEIN (DANIO RERIO CLONE MGC:66174 IMAGE:5602001 GENE ZGC:66459)/CN |
| E6 | 1 | TERA PROTEIN (HUMAN CLONE MGC:1093 IMAGE:3504430)/CN |
| E7 | 1 | TERA PROTEIN (MOUSE STRAIN C57BL/6 CLONE MGC:100067 IMAGE:30614283)/CN |
| E8 | 1 | TERABALLOON/CN |
| E9 | 1 | TERABOL/CN |
| E10 | 1 | TERACACIDIN/CN |
| E11 | 1 | TERACOL/CN |
| E12 | 1 | TERACOL 1000/CN |
| E13 | 1 | TERACOL 2000/CN |
| E14 | 1 | TERACOL 30/CN |
| E15 | 1 | TERACOL 5902/CN |
| E16 | 1 | TERACOL 650/CN |
| E17 | 1 | TERACOL TE 2000/CN |
| E18 | 1 | TERACONIC ACID/CN |
| E19 | 1 | TERACONIC ACID, ETHYL ESTER/CN |
| E20 | 1 | TERACONIC ANHYDRIDE/CN |
| E21 | 1 | TERACOTON/CN |

=> E "TER-286"/CN 25

=> E "TLK286"/CN 25

| | | |
|-----------|-------|---|
| E1 | 1 | TLK 286/CN |
| E2 | 1 | TLK2 PROTEIN (HUMAN CLONE MGC:44450 IMAGE:5297746)/CN |
| E3 | 0 --> | TLK286/CN |
| E4 | 1 | TLL 22/CN |
| E5 | 1 | TLL 28/CN |
| E6 | 1 | TLL1 PROTEIN (HUMAN CLONE IMAGE:4428491)/CN |
| E7 | 1 | TLL2 PROTEIN (HUMAN CLONE IMAGE:3836889 GENE TLL2)/CN |
| E8 | 1 | TLLP 10F1/CN |
| E9 | 1 | TLM 1005/CN |
| E10 | 1 | TLM 1026/CN |
| E11 | 1 | TLM 1027/CN |
| E12 | 1 | TLM 1404/CN |
| E13 | 1 | TLM 1405/CN |
| E14 | 1 | TLMA 2993/CN |
| E15 | 1 | TLMAC 30/CN |
| E16 | 1 | TLME/CN |
| E17 | 1 | TLMW 50/CN |
| E18 | 1 | TLN1 PROTEIN (MOUSE STRAIN FVB/N CLONE IMAGE:3707563 GENE |
| TLN1)/CN | | |
| E19 | 1 | TLN2 PROTEIN (MOUSE STRAIN C57BL/6 CLONE IMAGE:6414148 GENE |
| TLN2)/CN | | |
| E20 | 1 | TLND-1/CN |
| E21 | 1 | TLND-1P/CN |
| E22 | 1 | TLND-2/CN |
| E23 | 1 | TLND-3/CN |
| E24 | 1 | TLOC1 PROTEIN (HUMAN CLONE MGC:21260 IMAGE:4706586)/CN |
| E25 | 1 | TLOC1 PROTEIN (MOUSE STRAIN FVB/N CLONE IMAGE:5347105 GENE |
| TLOC1)/CN | | |

=> S E1

L1 1 "TLK 286"/CN

=> DIS L1 1 SQIDE

THE ESTIMATED COST FOR THIS REQUEST IS 6.15 U.S. DOLLARS

DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN

RN 439943-59-6 REGISTRY

CN Glycine, L-γ-glutamyl-3-[[2-[[bis[bis(2-chloroethyl)amino]phosphinyl]oxy]ethyl]sulfonyl]-L-alanyl-2-phenyl-, monohydrochloride, (2R)- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN Canglustratide hydrochloride

CN TER 286

CN **TLK 286**

FS STEREOSEARCH

MF C26 H40 Cl4 N5 O10 P S . Cl H

SR CAS Client Services

LC STN Files: ADISINSIGHT, CA, CAPLUS, IPA, PHAR, PROUSDDR, SYNTHLINE, TOXCENTER, USPATFULL

DT.CA Caplus document type: Conference; Journal; Patent


RL.P Roles from patents: BIOL (Biological study); USES (Uses)

RLD.P Roles for non-specific derivatives from patents: BIOL (Biological study); USES (Uses)

RL.NP Roles from non-patents: BIOL (Biological study); PROC (Process); USES (Uses)

CRN (158382-37-7)

Absolute stereochemistry.



● HCl

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

24 REFERENCES IN FILE CA (1907 TO DATE)

2 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

24 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

7.73

7.94

FILE 'CAPLUS' ENTERED AT 15:53:20 ON 15 NOV 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 15 Nov 2005 VOL 143 ISS 21
FILE LAST UPDATED: 14 Nov 2005 (20051114/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l1

L2 24 L1

=> s cancer? or tumor? or neoplas?

275164 CANCER?

408567 TUMOR?

428854 NEOPLAS?

L3 676443 CANCER? OR TUMOR? OR NEOPLAS?

=> s l3 (1) l2

L4 11 L3 (L) L2

=> s l4 not py>2002

3249906 PY>2002

L5 4 L4 NOT PY>2002

=> d ibib 1-4

L5 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:61250 CAPLUS

DOCUMENT NUMBER: 139:143479

TITLE: Efficacy of a glutathione S-transferase π -activated prodrug in platinum-resistant ovarian cancer cells

AUTHOR(S): Townsend, Danyelle M.; Shen, Hongxie; Staros, Alexandra L.; Gate, Laurent; Tew, Kenneth D.

CORPORATE SOURCE: Department of Pharmacology, Fox Chase Cancer Center, Philadelphia, PA, 19111, USA

SOURCE: Molecular Cancer Therapeutics (2002), 1(12), 1089-1095
CODEN: MCTOCF; ISSN: 1535-7163

PUBLISHER: American Association for Cancer Research

DOCUMENT TYPE: Journal

LANGUAGE: English

REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1998:402062 CAPLUS

DOCUMENT NUMBER: 129:117526

TITLE: Tumor efficacy and bone marrow-sparing properties of
TER286, a cytotoxin activated by glutathione
S-transferase

AUTHOR(S): Morgan, Amy S.; Sanderson, Polly E.; Borch, Richard
F.; Tew, Kenneth D.; Niitsu, Yoshiro; Takayama,
Tetsuji; Von Hoff, Daniel D.; Izbicka, Elzbieta;
Mangold, Gina; Paul, Christer; Broberg, Ulrika;
Mannervik, Bengt; Henner, W. David; Kauvar, Lawrence
M.

CORPORATE SOURCE: Terrapin Technologies, Inc., South San Francisco, CA,
94080, USA

SOURCE: Cancer Research (1998), 58(12), 2568-2575
CODEN: CNREA8; ISSN: 0008-5472

PUBLISHER: American Association for Cancer Research

DOCUMENT TYPE: Journal

LANGUAGE: English

REFERENCE COUNT: 59 THERE ARE 59 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1997:348755 CAPLUS

DOCUMENT NUMBER: 127:60274

TITLE: Activity of TER286 against human tumor colony-forming
units

AUTHOR(S): Izbicka, Elzbieta; Lawrence, Richard; Cerna, Caesar;
Von Hoff, Daniel D.; Sanderson, Polly E.

CORPORATE SOURCE: Inst. Drug Development, Cancer Therapy Res. Center,
San Antonio, TX, 78245, USA

SOURCE: Anti-Cancer Drugs (1997), 8(4), 345-348
CODEN: ANTDEV; ISSN: 0959-4973

PUBLISHER: Rapid Science Publishers

DOCUMENT TYPE: Journal

LANGUAGE: English

REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1996:695835 CAPLUS

DOCUMENT NUMBER: 126:554

TITLE: Glutathione-based anti-cancer drugs: Animal efficacy
and bone marrow sparing effects

AUTHOR(S): Lyttle, M. H.; Satyam, A.; Hocker, M. D.; Hui, H. C.;
Caldwell, C. G.; Morgan, A. S.; Stanboli, A.; Kauvar,
L. M.

CORPORATE SOURCE: Terrapin Technologies, South San Francisco, CA, 94080,
USA

SOURCE: Peptides: Chemistry, Structure and Biology,
Proceedings of the American Peptide Symposium, 14th,
Columbus, Ohio, June 18-23, 1995 (1996), Meeting Date
1995, 170-171. Editor(s): Kaumaya, Pravin T. P.;
Hodges, Robert S. Mayflower Scientific: Kingswinford,
UK.
CODEN: 63NTAF

DOCUMENT TYPE: Conference

LANGUAGE: English

=> file medline
COST IN U.S. DOLLARS
FULL ESTIMATED COST

| SINCE FILE ENTRY | TOTAL SESSION |
|---------------------|------------------|
| 13.31 | 21.25 |

FILE 'MEDLINE' ENTERED AT 15:54:52 ON 15 NOV 2005

FILE LAST UPDATED: 12 NOV 2005 (20051112/UP). FILE COVERS 1950 TO DATE.

On December 19, 2004, the 2005 MeSH terms were loaded.

The MEDLINE reload for 2005 is now available. For details enter HELP
RLOAD at an arrow prompt (=>). See also:

<http://www.nlm.nih.gov/mesh/>
http://www.nlm.nih.gov/pubs/techbull/nd04/nd04_mesh.html

OLDMEDLINE now back to 1950.

MEDLINE thesauri in the /CN, /CT, and /MN fields incorporate the
MeSH 2005 vocabulary.

This file contains CAS Registry Numbers for easy and accurate
substance identification.

```
=> s (TLK 286) or (TER 286)
      22 TLK
      4 TLKS
      22 TLK
          (TLK OR TLKS)
6956 286
      4 TLK 286
          (TLK(W) 286)
1720 TER
      46 TERS
1745 TER
          (TER OR TERS)
6956 286
      14 TER 286
          (TER(W) 286)
L6      16 (TLK 286) OR (TER 286)

=> s ((TLK 286) or (TER 286))/cn
      12 TLK 286/CN (9 TERMS)
          ("TER 286"+XUSE/CN)
      12 TER 286/CN (9 TERMS)
          ("TER 286"+XUSE/CN)
L7      12 ((TLK 286) OR (TER 286))/CN

=> s cancer? or tumor? or neoplas?
      544829 CANCER?
      755546 TUMOR?
      1454398 NEOPLAS?
L8      1756397 CANCER? OR TUMOR? OR NEOPLAS?

=> s l8 and l6
L9      15 L8 AND L6

=> s l8 and l7
L10     12 L8 AND L7

=> s l10 not py>2002
      1688339 PY>2002
L11     5 L10 NOT PY>2002

=> d ibib 1-5

L11 ANSWER 1 OF 5 MEDLINE on STN
ACCESSION NUMBER: 2002719938 MEDLINE
```

DOCUMENT NUMBER: PubMed ID: 12481432
TITLE: Efficacy of a glutathione S-transferase pi-activated
 prodrug in platinum-resistant ovarian **cancer**
 cells.
AUTHOR: Townsend Danyelle M; Shen Hongxie; Staros Alexandra L; Gate
 Laurent; Tew Kenneth D
CORPORATE SOURCE: Department of Pharmacology, Fox Chase Cancer Center, 7701
 Burholme Avenue, Philadelphia, PA 19111, USA.
CONTRACT NUMBER: CA06927 (NCI)
 CA75266 (NCI)
 CA83638 (NCI)
 CA85660 (NCI)
SOURCE: Molecular cancer therapeutics, (2002 Oct) 1 (12) 1089-95.
 Journal code: 101132535. ISSN: 1535-7163.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200305
ENTRY DATE: Entered STN: 20021218
 Last Updated on STN: 20030513
 Entered Medline: 20030512

L11 ANSWER 2 OF 5 MEDLINE on STN
ACCESSION NUMBER: 2000388491 MEDLINE
DOCUMENT NUMBER: PubMed ID: 10860939
TITLE: Cellular response to a glutathione S-transferase P1-1
 activated prodrug.
AUTHOR: Rosario L A; O'Brien M L; Henderson C J; Wolf C R; Tew K D
CORPORATE SOURCE: Department of Pharmacology, Fox Chase Cancer Center,
 Philadelphia, PA 19111, USA.
CONTRACT NUMBER: CA06927 (NCI)
 CA53893 (NCI)
 RR05539 (NCRR)
SOURCE: Molecular pharmacology, (2000 Jul) 58 (1) 167-74.
 Journal code: 0035623. ISSN: 0026-895X.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200008
ENTRY DATE: Entered STN: 20000818
 Last Updated on STN: 20000818
 Entered Medline: 20000810

L11 ANSWER 3 OF 5 MEDLINE on STN
ACCESSION NUMBER: 1998344500 MEDLINE
DOCUMENT NUMBER: PubMed ID: 9679557
TITLE: Glutathione based approaches to improving **cancer**
 treatment.
AUTHOR: Kauvar L M; Morgan A S; Sanderson P E; Henner W D
CORPORATE SOURCE: Terrapin Technologies, San Francisco, CA 94080, USA.
SOURCE: Chemico-biological interactions, (1998 Apr 24) 111-112
 225-38. Ref: 37
 Journal code: 0227276. ISSN: 0009-2797.
PUB. COUNTRY: Ireland
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
 General Review; (REVIEW)
 (REVIEW, TUTORIAL)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199808
ENTRY DATE: Entered STN: 19980820

Last Updated on STN: 19980820
Entered Medline: 19980810

L11 ANSWER 4 OF 5 MEDLINE on STN
ACCESSION NUMBER: 1998297503 MEDLINE
DOCUMENT NUMBER: PubMed ID: 9635580
TITLE: **Tumor** efficacy and bone marrow-sparing properties
of TER286, a cytotoxin activated by glutathione
S-transferase.
AUTHOR: Morgan A S; Sanderson P E; Borch R F; Tew K D; Niitsu Y;
Takayama T; Von Hoff D D; Izbicka E; Mangold G; Paul C;
Broberg U; Mannervik B; Henner W D; Kauvar L M
CORPORATE SOURCE: Terrapin Technologies, Inc., South San Francisco,
California 94080, USA.
SOURCE: Cancer research, (1998 Jun 15) 58 (12) 2568-75.
Journal code: 2984705R. ISSN: 0008-5472.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199807
ENTRY DATE: Entered STN: 19980713
Last Updated on STN: 19980713
Entered Medline: 19980701

L11 ANSWER 5 OF 5 MEDLINE on STN
ACCESSION NUMBER: 97324218 MEDLINE
DOCUMENT NUMBER: PubMed ID: 9180387
TITLE: Activity of TER286 against human **tumor**
colony-forming units.
AUTHOR: Izbicka E; Lawrence R; Cerna C; Von Hoff D D; Sanderson P E
CORPORATE SOURCE: Institute for Drug Development, Cancer Therapy and Research
Center, San Antonio, TX 78245, USA.
SOURCE: Anti-cancer drugs, (1997 Apr) 8 (4) 345-8.
Journal code: 9100823. ISSN: 0959-4973.
PUB. COUNTRY: ENGLAND: United Kingdom
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199709
ENTRY DATE: Entered STN: 19970916
Last Updated on STN: 19970916
Entered Medline: 19970902

=> d ibib abs 3

L11 ANSWER 3 OF 5 MEDLINE on STN
ACCESSION NUMBER: 1998344500 MEDLINE
DOCUMENT NUMBER: PubMed ID: 9679557
TITLE: Glutathione based approaches to improving **cancer**
treatment.
AUTHOR: Kauvar L M; Morgan A S; Sanderson P E; Henner W D
CORPORATE SOURCE: Terrapin Technologies, San Francisco, CA 94080, USA.
SOURCE: Chemico-biological interactions, (1998 Apr 24) 111-112
225-38. Ref: 37
Journal code: 0227276. ISSN: 0009-2797.
PUB. COUNTRY: Ireland
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, TUTORIAL)
LANGUAGE: English
FILE SEGMENT: Priority Journals

ENTRY MONTH: 199808
ENTRY DATE: Entered STN: 19980820
Last Updated on STN: 19980820
Entered Medline: 19980810

- . AB The use of cytotoxic chemotherapy for **cancer** therapy has been very successful in the treatment and often cure of patients with particular **neoplasms**, such as testicular carcinomas and some lymphomas. In addition, the use of adjuvant chemotherapy in patients whose primary **tumor** has been surgically removed contributes significantly to cure rates in some of the more common malignancies such as breast carcinoma and colon **cancer**. Nonetheless, for most patients with metastatic malignancies, current antineoplastic drugs provide only brief remissions with few or no long term cures. In addition, the side effects of therapy lead to substantial morbidity in nearly all patients. Insights derived from model system studies on two glutathione based lead compounds, TER286 and TER199, suggest new clinical strategies and raise interesting basic research questions regarding the cell biology foundations of **cancer** chemotherapy.